HORIZANT (Gabapentin Enacarbil Extended-Release Tablets) for the Treatment of Alcohol Use Disorder

PHASE2CompletedINTERVENTIONAL
Enrollment

346

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

March 31, 2017

Study Completion Date

March 31, 2017

Conditions
Alcohol Use Disorder
Interventions
DRUG

gabapentin enacarbil

Horizant Extended Release Tablets, 600 mg, white to off-white, oval shaped tablets, taken 2 times per day

DRUG

Placebo

Placebo tablet, white to off-white, oval shaped tablets, taken 2 times per day

Trial Locations (10)

10025

Mount Sinai St. Luke's Hospital, New York

19104

University of Pennsylvania, Philadelphia

21224

Johns Hopkins University School of Medicine, Baltimore

22911

University of Virginia, Charlottesville

33136

University of Miami, Miller School of Medicine, Miami

75235

The University of Texas Southwestern Medical Center, Dallas

94103

Friends Research Institute, San Francisco

Unknown

University of California Los Angeles, Los Angeles

02118

Boston University Medical Center, Boston

03756

Dartmouth-Hitchcock Medical Center, Lebanon

Sponsors
All Listed Sponsors
collaborator

Arbor Pharmaceuticals, Inc.

INDUSTRY

lead

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

NIH

NCT02252536 - HORIZANT (Gabapentin Enacarbil Extended-Release Tablets) for the Treatment of Alcohol Use Disorder | Biotech Hunter | Biotech Hunter